{"created":"2024-03-05T06:15:19.147455+00:00","id":2012929,"links":{},"metadata":{"_buckets":{"deposit":"d4cbe74b-7ae4-4a6c-a9ad-d3b3fe51e0d9"},"_deposit":{"created_by":9,"id":"2012929","owners":[9],"pid":{"revision_id":0,"type":"depid","value":"2012929"},"status":"published"},"_oai":{"id":"oai:our.repo.nii.ac.jp:02012929","sets":["1623632832836:1707978071892","1707979148924:1707983962284"]},"author_link":[],"item_30002_access_rights4":{"attribute_name":"Access Rights","attribute_value_mlt":[{"subitem_access_right":"metadata only access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_14cb"}]},"item_30002_creator2":{"attribute_name":"Creator","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"高島, 淳生","creatorNameLang":"ja"},{"creatorName":"タカシマ, アツオ","creatorNameLang":"ja-Kana"},{"creatorName":"Takashima, Atsuo","creatorNameLang":"en"}]}]},"item_30002_date11":{"attribute_name":"Date","attribute_value_mlt":[{"subitem_date_issued_datetime":"2015-01-01","subitem_date_issued_type":"Issued"}]},"item_30002_date_granted32":{"attribute_name":"Date Granted","attribute_value_mlt":[{"subitem_dategranted":"2015-06-29"}]},"item_30002_degree_grantor33":{"attribute_name":"Degree Grantor","attribute_value_mlt":[{"subitem_degreegrantor":[{"subitem_degreegrantor_language":"ja","subitem_degreegrantor_name":"大分大学"}]}]},"item_30002_degree_name31":{"attribute_name":"Degree Name","attribute_value_mlt":[{"subitem_degreename":"博士(医学)","subitem_degreename_language":"ja"}]},"item_30002_description9":{"attribute_name":"Description","attribute_value_mlt":[{"subitem_description":"Background: Two randomized phase III trials of first-line chemotherapy for advanced gastric cancer (JCOG9205 and JCOG9912) conducted by the Japan Clinical Oncology Group used 5-fluorouracil continuous infusion (5-FUci) as the control arm. New active agents (e.g., S-1, irinotecan, and taxanes) were introduced as second-line chemotherapy in the late 1990s after JCOG9205. This combined analysis evaluated whether patients in the 5-FUci arm of JCOG9912 exhibited better survival after adjusting for baseline factors and also investigated the cause of survival prolongation.","subitem_description_language":"en"},{"subitem_description":"Patients and methods: The subjects were patients assigned to the 5-FUci arms who met the eligibility criteria of both JCOG9205 and JCOG9912. Overall survival (OS), time to treatment failure (TTF), and survival after treatment failure in the first-line chemotherapy (OS-TTF) were compared after adjusting baseline characteristics using the Cox proportional hazard model. Second-line chemotherapy details were also reviewed.","subitem_description_language":"en"},{"subitem_description":"Results: The combined analysis included 89 and 230 patients in JCOG9205 and JCOG9912, respectively. After adjusting baseline characteristics, TTF was similar between groups (HR 0.95; 95 % CI, 0.73-1.26). However, both OS (HR, 0.74; 95 % CI, 0.56-0.99) and OS-TTF (HR, 0.76; 95 % CI, 0.57-1.01) were longer in JCOG9912. More patients in JCOG9912 received second-line chemotherapy (83 vs. 52 %) with new drugs (77 vs. 10 %) than in JCOG9205. OS-TTF was substantially prolonged in patients who received second-line chemotherapy (HR, 0.66; 95 % CI, 0.46-0.95).","subitem_description_language":"en"},{"subitem_description":"Conclusion: OS and OS-TTF were longer in JCOG9912 than JCOG9205. Second-line chemotherapy with new drugs is a potential reason for the observed prolongation of survival.","subitem_description_language":"en"}]},"item_30002_dissertation_number30":{"attribute_name":"Dissertation Number","attribute_value_mlt":[{"subitem_dissertationnumber":"乙第334号"}]},"item_30002_identifier16":{"attribute_name":"Identifier","attribute_value_mlt":[{"subitem_identifier_type":"HDL","subitem_identifier_uri":"http://hdl.handle.net/10559/17183"}]},"item_30002_language12":{"attribute_name":"Language","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_30002_publisher10":{"attribute_name":"Publisher","attribute_value_mlt":[{"subitem_publisher":"大分大学","subitem_publisher_language":"ja"}]},"item_30002_relation18":{"attribute_name":"Relation","attribute_value_mlt":[{"subitem_relation_type":"isVersionOf","subitem_relation_type_id":{"subitem_relation_type_id_text":"https://doi.org/10.1007/s10120-013-0309-z","subitem_relation_type_select":"DOI"}}]},"item_30002_resource_type13":{"attribute_name":"Resource Type","attribute_value_mlt":[{"resourcetype":"doctoral thesis","resourceuri":"http://purl.org/coar/resource_type/c_db06"}]},"item_30002_title0":{"attribute_name":"Title","attribute_value_mlt":[{"subitem_title":"Survival prolongation after treatment failure of first-line chemotherapy in patients with advanced gastric cancer: combined analysis of the Japan Clinical Oncology Group Trials JCOG9205 and JCOG9912","subitem_title_language":"en"},{"subitem_title":"進行胃癌一次治療終了後における予後の延長:JCOG9205/JCOG9912統合解析","subitem_title_language":"ja"}]},"item_title":"Survival prolongation after treatment failure of first-line chemotherapy in patients with advanced gastric cancer: combined analysis of the Japan Clinical Oncology Group Trials JCOG9205 and JCOG9912","item_type_id":"30002","owner":"9","path":["1707983962284","1707978071892"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2023-04-17"},"publish_date":"2023-04-17","publish_status":"0","recid":"2012929","relation_version_is_last":true,"title":["Survival prolongation after treatment failure of first-line chemotherapy in patients with advanced gastric cancer: combined analysis of the Japan Clinical Oncology Group Trials JCOG9205 and JCOG9912"],"weko_creator_id":"9","weko_shared_id":-1},"updated":"2024-03-18T05:51:54.827369+00:00"}